통풍 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약효 클래스별(NSAIDs, 코르티코스테로이드, 콜히친), 질환별(급성, 만성), 유통채널별, 지역별, 부문별 예측(2023-2030년)

Gout Therapeutics Market Growth & Trends

The global gout therapeutics market size is expected to reach USD 4.13 billion by 2030 and expand at a CAGR of 6.25% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights

• NSAIDs segment accounted for the largest share of the market in 2022 due to the high prescription rate, low cost, and strong presence in the market.
• Based on disease condition, the acute condition segment held 65.77% of the total market share in 2022, owing to a high patient pool compared to the chronic condition
• In 2022, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
• North America dominated the global market in 2022 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
• Some key players in the space include GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Regeneron Pharmaceuticals Inc; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Ltd.; and Horizon Pharma plc; Zydus Group and others

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Market Definitions
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Secondary Sources
  • 1.4.3 Primary Research
  • 1.4.4 Details Of Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country-Wise Market Estimation Using The Bottom-Up Approach
• 1.8 Regional Market: Cagr Calculation
• 1.9 Research Assumptions
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations
• 1.12 Objectives
  • 1.12.1 Objective 1
  • 1.12.2 Objective 2

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Drug Class And Disease Condition Segment Snapshot
• 2.3 Distribution Chanel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Global Gout Therapeutics Market Variables, Trends, & Scope

• 3.1 Gout Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Regulatory Framework
• 3.4 Market Driver Analysis
  • 3.4.1 Rising Prevalence Of Gout
  • 3.4.2 Advanced And New Therapies With Strong R&D Pipeline
  • 3.4.3 Rising Awareness Among People
• 3.5 Market Restraint Analysis
  • 3.5.1 Delayed Disease Diagnosis In Developing And Underdeveloped Countries
• 3.6 Porter's Five Forces Analysis
• 3.7 Pipeline Analysis

Chapter 4 Gout Therapeutics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

• 4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
• 4.2. Nsaids
  • 4.2.1. Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.3. Corticosteroids
  • 4.3.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.4. Colchicine
  • 4.4.1 Colchicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.5. Urate-Lowering Agents
  • 4.5.1 Urate-Lowering Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Gout Therapeutics - Segment Analysis, By Disease Condition, 2018 - 2030 (USD Million)

• 5.1. Global Gout Therapeutics Market: Disease Condition Movement Analysis
• 5.2. Acute Gout
  • 5.2.1. Acute Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.3. Chronic Gout
  • 5.3.1. Chronic Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Gout Therapeutics Market- Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

• 6.1. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
• 6.2. Hospital Pharmacy
  • 6.2.1. Hospital Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.3. Retail Pharmacy
  • 6.3.1. Retail Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.4. Online Pharmacy
  • 6.4.1. Online Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Gout Therapeutics Market: - Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Gout Therapeutics Market: Regional Movement Analysis
  • 7.1.1 Definition & Scope
• 7.2 North America
  • 7.2.1 North America, Swot Analysis
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Target Disease Prevalence
    • 7.2.2.4 Competitive Scenario
    • 7.2.2.5 Regulatory Framework
    • 7.2.2.6 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Target Disease Prevalence
    • 7.2.3.4 Competitive Scenario
    • 7.2.3.5 Regulatory Framework
    • 7.2.3.6 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe, Swot Analysis
  • 7.3.2 Uk
    • 7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Target Disease Prevalence
    • 7.3.2.4 Competitive Scenario
    • 7.3.2.5 Regulatory Framework
    • 7.3.2.6 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Target Disease Prevalence
    • 7.3.3.4 Competitive Scenario
    • 7.3.3.5 Regulatory Framework
    • 7.3.3.6 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Target Disease Prevalence
    • 7.3.4.4 Competitive Scenario
    • 7.3.4.5 Regulatory Framework
    • 7.3.4.6 Reimbursement Scenario
  • 7.3.5 Italy
    • 7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Target Disease Prevalence
    • 7.3.5.4 Competitive Scenario
    • 7.3.5.5 Regulatory Framework
    • 7.3.5.6 Reimbursement Scenario
  • 7.3.6 Spain
    • 7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Target Disease Prevalence
    • 7.3.6.4 Competitive Scenario
    • 7.3.6.5 Regulatory Framework
    • 7.3.6.6 Reimbursement Scenario
  • 7.3.7 Sweden
    • 7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Target Disease Prevalence
    • 7.3.7.4 Competitive Scenario
    • 7.3.7.5 Regulatory Framework
    • 7.3.7.6 Reimbursement Scenario
  • 7.3.8 Denmark
    • 7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Target Disease Prevalence
    • 7.3.8.4 Competitive Scenario
    • 7.3.8.5 Regulatory Framework
    • 7.3.8.6 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Target Disease Prevalence
    • 7.3.9.4 Competitive Scenario
    • 7.3.9.5 Regulatory Framework
    • 7.3.9.6 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific, Swot Analysis
  • 7.4.2 India
    • 7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Target Disease Prevalence
    • 7.4.2.4 Competitive Scenario
    • 7.4.2.5 Regulatory Framework
    • 7.4.2.6 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Target Disease Prevalence
    • 7.4.3.4 Competitive Scenario
    • 7.4.3.5 Regulatory Framework
    • 7.4.3.6 Reimbursement Scenario
  • 7.4.4 Japan
    • 7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Target Disease Prevalence
    • 7.4.4.4 Competitive Scenario
    • 7.4.4.5 Regulatory Framework
    • 7.4.4.6 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Target Disease Prevalence
    • 7.4.5.4 Competitive Scenario
    • 7.4.5.5 Regulatory Framework
    • 7.4.5.6 Reimbursement Scenario
  • 7.4.6 South Korea
    • 7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Target Disease Prevalence
    • 7.4.6.4 Competitive Scenario
    • 7.4.6.5 Regulatory Framework
    • 7.4.6.6 Reimbursement Scenario
  • 7.4.7 Thailand
    • 7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Target Disease Prevalence
    • 7.4.7.4 Competitive Scenario
    • 7.4.7.5 Regulatory Framework
    • 7.4.7.6 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America, Swot Analysis
  • 7.5.2 Mexico
    • 7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Target Disease Prevalence
    • 7.5.2.4 Competitive Scenario
    • 7.5.2.5 Regulatory Framework
    • 7.5.2.6 Reimbursement Scenario
  • 7.5.3 Brazil
    • 7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Target Disease Prevalence
    • 7.5.3.4 Competitive Scenario
    • 7.5.3.5 Regulatory Framework
    • 7.5.3.6 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.4.2 Key Country Dynamics
    • 7.5.4.3 Target Disease Prevalence
    • 7.5.4.4 Competitive Scenario
    • 7.5.4.5 Regulatory Framework
    • 7.5.4.6 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 Middle East & Africa, Swot Analysis
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Target Disease Prevalence
    • 7.6.2.4 Competitive Scenario
    • 7.6.2.5 Regulatory Framework
    • 7.6.2.6 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Target Disease Prevalence
    • 7.6.3.4 Competitive Scenario
    • 7.6.3.5 Regulatory Framework
    • 7.6.3.6 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Target Disease Prevalence
    • 7.6.4.4 Competitive Scenario
    • 7.6.4.5 Regulatory Framework
    • 7.6.4.6 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Target Disease Prevalence
    • 7.6.5.4 Competitive Scenario
    • 7.6.5.5 Regulatory Framework
    • 7.6.5.6 Reimbursement Scenario

Chapter 8 Competitive Landscape

• 8.1 Public Companies
  • 8.1.1 Company Market Position Analysis
  • 8.1.2 Competitive Dashboard Analysis
  • 8.1.3 Strategic Framework
• 8.2 Private Companies
  • 8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
  • 8.2.2 Regional Network Map
• 8.3 Company Profiles
  • 8.3.1 Takeda Pharmaceutical Company Ltd.
    • 8.3.1.1 Company Overview
    • 8.3.1.2 Financial Performance
    • 8.3.1.3 Product Benchmarking
    • 8.3.1.4 Strategic Initiatives
  • 8.3.2 Novartis Ag
    • 8.3.2.1 Company Overview
    • 8.3.2.2 Financial Performance
    • 8.3.2.3 Product Benchmarking
    • 8.3.2.4 Strategic Initiatives
  • 8.3.3 Regeneron Pharmaceuticals Inc.
    • 8.3.3.1 Company Overview
    • 8.3.3.2 Financial Performance
    • 8.3.3.3 Product Benchmarking
    • 8.3.3.4 Strategic Initiatives
  • 8.3.4 Astrazeneca Plc
    • 8.3.4.1 Company Overview
    • 8.3.4.2 Financial Performance
    • 8.3.4.3 Product Benchmarking
    • 8.3.4.4 Strategic Initiatives
  • 8.3.5 Horizon Therapeutics Plc
    • 8.3.5.1 Company Overview
    • 8.3.5.2 Financial Performance
    • 8.3.5.3 Product Benchmarking
    • 8.3.5.4 Strategic Initiatives
  • 8.3.6 Merck & Co. Inc
    • 8.3.6.1 Company Overview
    • 8.3.6.2 Financial Performance
    • 8.3.6.3 Product Benchmarking
    • 8.3.6.4 Strategic Initiatives
  • 8.3.7 Zydus Group
    • 8.3.7.1 Company Overview
    • 8.3.7.2 Financial Performance
    • 8.3.7.3 Product Benchmarking
    • 8.3.7.4 Strategic Initiatives
  • 8.3.8 Teijin Ltd
    • 8.3.8.1 Company Overview
    • 8.3.8.2 Financial Performance
    • 8.3.8.3 Product Benchmarking
    • 8.3.8.4 Strategic Initiatives
  • 8.3.9 Glaxosmithkline Plc
    • 8.3.9.1 Company Overview
    • 8.3.9.2 Financial Performance
    • 8.3.9.3 Product Benchmarking
    • 8.3.9.4 Strategic Initiatives